Arnold, Douglas L.

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine

Multiple Sclerosis Research StudiesPolyomavirus and related diseases

Cited by 2,439

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

Hauser, S. L., Bar-Or, A., Comi, G., Giovannoni, G., Hartung, H.-P., Hemmer, B., Lublin, F., Montalban, X., Rammohan, K. W., Selmaj, K., et al. (2017) · New England Journal of Medicine

Multiple Sclerosis Research StudiesPsoriasis: Treatment and Pathogenesis

Cited by 2,021

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., de Seze, J., Giovannoni, G., Hartung, H.-P., Hemmer, B., et al. (2017) · New England Journal of Medicine

Multiple Sclerosis Research StudiesPolyomavirus and related diseases

Cited by 1,905

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

Cohen, J. A., Coles, A. J., Arnold, D. L., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., Fisher, E., et al. (2012) · The Lancet

Multiple Sclerosis Research StudiesChronic Lymphocytic Leukemia Research

Cited by 1,205

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Coles, A. J., Twyman, C. L., Arnold, D. L., Cohen, J. A., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., et al. (2012) · The Lancet

Multiple Sclerosis Research StudiesChronic Lymphocytic Leukemia Research

Cited by 1,198

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Kappos, L., Bar-Or, A., Cree, B. A. C., Fox, R. J., Giovannoni, G., Gold, R., Vermersch, P., Arnold, D. L., Arnould, S., Scherz, T., et al. (2018) · The Lancet

Multiple Sclerosis Research StudiesSphingolipid Metabolism and Signaling

Cited by 942

How patients with multiple sclerosis acquire disability

Lublin, F. D., Häring, D. A., Ganjgahi, H., Ocampo, A., Hatami, F., Čuklina, J., Aarden, P., Dahlke, F., Arnold, D. L., Wiendl, H., et al. (2022) · Brain

Multiple Sclerosis Research StudiesPolyomavirus and related diseases

Cited by 549

Exploring uncertainty measures in deep networks for Multiple sclerosis lesion detection and segmentation

Nair, T., Precup, D., Arnold, D. L., & Arbel, T. (2020) · Medical Image Analysis

Medical Image Segmentation TechniquesAdvanced Neural Network Applications

Cited by 451

metabolic recovery after exercise and the assessment of mitochondrial function in Vivo in human skeletal muscle by means of 31P NMR

Arnold, D. L., Matthews, P. M., & Radda, G. K. (1984) · Magnetic Resonance in Medicine

Cardiovascular and exercise physiologyAdvanced MRI Techniques and Applications

Cited by 442

Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis

Montalban, X., Arnold, D. L., Weber, M. S., Staikov, I., Piasecka-Stryczynska, K., Willmer, J., Martin, E. C., Dangond, F., Syed, S., & Wolinsky, J. S. (2019) · New England Journal of Medicine

Multiple Sclerosis Research StudiesChronic Lymphocytic Leukemia Research

Cited by 324

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings

Coles, A. J., Cohen, J. A., Fox, E. J., Giovannoni, G., Hartung, H.-P., Havrdova, E., Schippling, S., Selmaj, K. W., Traboulsee, A., Compston, D. A. S., et al. (2017) · Neurology

Multiple Sclerosis Research StudiesPolyomavirus and related diseases

Cited by 277

Investigation of human mitochondrial myopathies by phosphorus magnetic resonance spectroscopy

Arnold, D. L., Taylor, D. J., & Radda, G. K. (1985) · Annals of Neurology

Mitochondrial Function and PathologyAdvanced MRI Techniques and Applications

Cited by 266

A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease

Salloway, S., Sperling, R., Keren, R., Porsteinsson, A. P., van Dyck, C. H., Tariot, P. N., Gilman, S., Arnold, D., Abushakra, S., Hernandez, C., et al. (2011) · Neurology

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 258

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy

Havrdova, E., Arnold, D. L., Cohen, J. A., Hartung, H.-P., Fox, E. J., Giovannoni, G., Schippling, S., Selmaj, K. W., Traboulsee, A., Compston, D. A. S., et al. (2017) · Neurology

Multiple Sclerosis Research StudiesPolyomavirus and related diseases

Cited by 221

Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions

Elliott, C., Wolinsky, J. S., Hauser, S. L., Kappos, L., Barkhof, F., Bernasconi, C., Wei, W., Belachew, S., & Arnold, D. L. (2019) · Multiple Sclerosis Journal

Multiple Sclerosis Research StudiesAdvanced MRI Techniques and Applications

Cited by 217

Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: A phase 2b, randomised, double-blind, placebo-controlled trial

Reich, D. S., Arnold, D. L., Vermersch, P., Bar-Or, A., Fox, R. J., Matta, A., Turner, T., Wallström, E., Zhang, X., Mareš, M., et al. (2021) · The Lancet Neurology

Multiple Sclerosis Research StudiesChronic Lymphocytic Leukemia Research

Cited by 204

Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial

Wolinsky, J. S., Arnold, D. L., Brochet, B., Hartung, H.-P., Montalban, X., Naismith, R. T., Manfrini, M., Overell, J., Koendgen, H., Sauter, A., et al. (2020) · The Lancet Neurology

Multiple Sclerosis Research StudiesChronic Lymphocytic Leukemia Research

Cited by 150

A validation study of multicenter diffusion tensor imaging: Reliability of fractional anisotropy and diffusivity values

Fox, R. J., Sakaie, K., Lee, J.-C., Debbins, J. P., Liu, Y., Arnold, D. L., Melhem, E. R., Smith, C. H., Philips, M. D., Lowe, M., et al. (2012) · American Journal of Neuroradiology

Advanced Neuroimaging Techniques and ApplicationsAdvanced MRI Techniques and Applications

Cited by 137

2010 McDonald Criteria for diagnosing pediatric multiple sclerosis

Sadaka, Y., Verhey, L. H., Shroff, M. M., Branson, H. M., Arnold, D. L., Narayanan, S., Sled, J. G., Bar‐Or, A., Sadovnick, A. D., McGowan, M., et al. (2012) · Annals of Neurology

Multiple Sclerosis Research StudiesPeripheral Neuropathies and Disorders

Cited by 136

In vivo muscle magnetic resonance spectroscopy in the clinical investigation of mitochondria1 disease

Matthews, P. M., Allaire, C., Shoubridge, E. A., Karpati, G., Carpenter, S., & Arnold, D. L. (1991) · Neurology

Advanced MRI Techniques and ApplicationsMitochondrial Function and Pathology

Cited by 121

A mitochondrial encephalomyopathy

Hayes, D. J., Hilton-Jones, D., Arnold, D. L., Galloway, G., Styles, P., Duncan, J., & Radda, G. K. (1985) · Journal of the Neurological Sciences

Mitochondrial Function and PathologyCoenzyme Q10 studies and effects

Cited by 72

Effect of Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple Sclerosis: A Post Hoc Analysis of a Phase 2 Trial

Arnold, D. L., Elliott, C., Martin, E. C., Hyvert, Y., Tomic, D., & Montalban, X. (2024) · Neurology

Multiple Sclerosis Research StudiesChronic Lymphocytic Leukemia Research

Cited by 30

MRI evidence of acute inflammation in leukocortical lesions of patients with early multiple sclerosis

Maranzano, J., Rudko, D. A., Nakamura, K., Cook, S., Cadavid, D., Wolansky, L., Arnold, D. L., & Narayanan, S. (2017) · Neurology

Multiple Sclerosis Research StudiesPolyomavirus and related diseases

Cited by 23

Efficacy and safety results after >3.5 years of treatment with the Bruton’s tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study

Montalban, X., Piasecka-Stryczynska, K., Kuhle, J., Benkert, P., Arnold, D. L., Weber, M. S., Seitzinger, A., Guehring, H., Shaw, J., Tomic, D., et al. (2024) · Multiple Sclerosis Journal

Multiple Sclerosis Research StudiesChronic Lymphocytic Leukemia Research

Cited by 21